Stroke Prevention With Hydroxyurea Enabled Through Research and Education (SPHERE)
Status:
Active, not recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
This study will 1) Evaluate the prevalence of elevated (conditional or abnormal) transcranial
Doppler (TCD) velocities in a cross-sectional analysis of children with Sickle Cell Anemia
(SCA) living in Tanzania; 2) Obtain longitudinal data on TCD velocities in this population;
and 3) Measure the effects of hydroxyurea therapy on TCD velocities and associated primary
stroke risk.
Phase:
Phase 2
Details
Lead Sponsor:
Children's Hospital Medical Center, Cincinnati
Collaborators:
Bugando Medical Centre The American Society of Hematology